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Epilepsy is one of the most common neurolog-
ical disorders affecting approximately 1% of the
population worldwide (1). Despite the progress in
understanding the pathogenesis of seizures, the cur-
rent therapy remains still ineffective in at least 30%
of epilepsies. 
Moreover, a large number of new antiepileptic
drugs (ADEs) marketed during recent years, did not
change the proportion of patients responding to the
treatment and many of those medications cause
serous side effects, which include ataxia, nausea,
mental dulling and hepatotoxicity. Thus, new ADEs
with higher efficacy, better safety and tolerability
are urgently needed (2-5). 
The pyridine moiety is known as one of the
important structural fragments that appears in the
structures of anticonvulsant active molecules (6-9).
In our earlier studies on a search for new potential
anti-seizure agents, a series of 3-phenyl-pyrrolidine-
2,5-diones as well as 2-azaspiro[4.4]nonane- and
[4.5]decane-1,3-diones containing the pyridine moi-
ety at the imide nitrogen atom have been described
(10-16). Many of these compounds exhibited potent
anticonvulsant properties in the maximal elec-
troshock seizure (MES) and/or pentylenetetrazole
(scPTZ) tests, recognized as the most widely
employed animal seizure models for early identifi-
cation of candidate anticonvulsants. The structure-
activity relationship analysis (SAR) revealed that
the most active were compounds with the methyl
substituent at position-3 and -6 of the 2-pyridinyl
moiety. In line with the above data, as a continuation
of our systematic research in this group of deriva-
tives, in the present study we have designed and syn-
thesized a series of 1-(2-pyridinyl)-pyrrolidine-2,5-
diones differently substituted at the position-3 of
succinimide ring. The aim of these modifications
was to establish the most relevant substitution pat-
tern in respect to anticonvulsant activity of that type
of derivatives. Furthermore, this work enabled to
investigate the role of the spiro nucleus as a struc-
tural fragment essential for activity of azaspiranes
described previously (16).
All the compounds obtained were evaluated for
their anti-seizure activity and neutotoxic properties
within the Antiepileptic Drug Development (ADD)
Program, Epilepsy Branch, Neurological Disorders
Program, National Institute of the Neurological and
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these compounds was examined by a maximal electroshock (MES) and pentylenetetrazole (scPTZ) tests,
whereas their neurotoxicity was determined using a rotarod screen. The results obtained revealed that the anti-
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The most active were 3,3-dialkyl-pyrrolidine-2,5-diones [IX-XVIII] as well as compounds with 3-methylcy-
clohexane moiety as a spiro nucleus at position-3 of the imide ring [I-IV]. The 3-cyclohexylsuccinimides [V-
VIII] with cyclohexane ring as a flexible fragment were less active, whereas unsubstituated derivatives [XIX-
XXII] were devoid of activity in both tests applied. In addition, the anti-seizure protection depended on the
position of methyl group at the pyridine moiety. The most potent were compounds with the methyl substituent
at the position-4 [II, VI, XVII] or -6 [XI, XIV]. It should be noted, that in the whole series the most active was
1-(4-methyl-2-pyridinyl)-3-cyclohexyl-pyrrolidne-2,5-dione [VI], which showed the anti-scPTZ protection at
the dose of 30 mg/kg.
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Communicative Disorders and Stroke (NINCDS),
Bethesda, USA.
Compounds I-XXII were synthesized accord-
ing to Scheme 1. The starting 1-carboxy-1-(3-
methylcyclohexane)acetic acid, 2,2-dimethyl-, 2-
ethyl-2-methyl- and 2,2-diethyl-succinic acids were
prepared as reported previously (17, 18). The syn-
thetic procedures of 2-cyclohexylsuccinic acid have
been described in the literature (19). The final 1-(2-
pyridinyl)-succinimides (I-XVIII) were obtained in
a one-pot cyclization reaction of the prepared acids
and appropriately substituted 2-amino-pyridines by
heating them at ca. 180OC for 1.5 h. Compounds
XIX-XII were synthesized in the same manner
using the succinic anhydride as a reaction substrate.
The structures of the compounds synthesized
were confirmed by the examination of their 1H NMR
spectra, which revealed characteristic chemical
shifts in agreement with their proposed structures.
The chemical shifts of the cyclohexane rings [I-
VIII] were observed as multiplets within the range
of δ 0.95-1.91 ppm [I-IV] and δ 1.06-2.13 ppm [V-
VIII]. The signals due to the methyl substituents at
the position-3 of pyrrolidine-2,5-dione appeared at δ
1.41-1.46 ppm, as singlets [X, XI, XIII-XV] or dou-
blets [XII, XIX]. The ethyl groups of compounds
XII-XVIII were observed in two ranges δ 0.96-1.06
and δ 1.65-1.95 that correspond to the signals of
methyl and methylene protons, respectively. The
methyl substituents at the 2-pyridinyl moiety were
recorded as singlets at δ 2.19 ppm to δ 2.59 ppm.
The appearance of singlets, doublets or multiplets
within the range δ 2.59-3.04 ppm correspond to the
protons of imide rings. The methyl groups at posi-
tion-7 of 2-azaspiro[4.5]decane-1,3-diones [I-IV]
were recorded as multiplet [I] or doublets [II-IV]
Scheme 1. Synthesis of compounds I ñ XXII.
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Table 1. Physicochemical and analytical data for compounds I-XXII.
Molecular Yield %
Compound formula M. p.
Analysis (calc./found)
Rfa
no. Weight [OC]
%C %H %N
I C16H20O2N2 59 70.56 7.40 10.29 0.80
272.35 103-105 70.66 7.52 10.38
II C16H20O2N2 67 70.56 7.40 10.29 0.74
272.35 102-104 70.49 7.42 10.39
III C16H20O2N2 62 70.56 7.40 10.29 0.85
272.35 190-192 70.72 7.49 10.28
IV C17H22O2N2 60 71.30 7.74 9.78 0.81
283.38 120-122 71.50 7.69 9.60
V C16H20O2N2 57 70.56 7.40 10.29 0.73
272.35 130-132 70.70 7.38 10.39
VI C16H20O2N2 63 70.56 7.40 10.29 0.74
272.35 119-121 70.42 7.32 10.18
VII C16H20O2N2 65 70.56 7.40 10.29 0.76
272.35 96-98 70.55 7.38 10.20
VIII C17H22O2N2 60 71.30 7.74 9.78 0.60
283.38 140-142 71.19 7.63 9.70
IX C12H14O2N2 66 66.04 6.47 12.84 0.58
218.26 88-90 65.97 6.40 12.88
X C12H14O2N2 67 66.04 6.47 12.84 0.56
218.26 134-136 66.11 6.53 12.80
XI C12H14O2N2 60 66.04 6.47 12.84 0.60
218.26 122-124 66.10 6.50 12.82
XII C13H16O2N2 59 67.22 6.94 12.04 0. 77
232.28 98-100 67.15 6.89 12.10
XIII C13H16O2N2 65 67.22 6.94 12.04 0.78
232.28 58-60 67.27 6.90 12.01
XIV C13H16O2N2 60 67.22 6.94 12.04 0.80
232.28 78-80 67.16 6.90 12.08
XV C14H18O2N2 62 68.27 7.37 11.37 0.79
246.31 90-92 68.32 7.39 11.30
XVI C14H18O2N2 58 68.27 7.37 11.37 0.69
246.31 76-78 68.20 7.34 11.30
XV C14H18O2N2 61 68.27 7.37 11.37 0.70
246.31 38-40 68.19 7.29 11.34
XVIII C14H18O2N2 62 68.27 7.37 11.37 0.72
246.31 58-60 68.17 7.30 11.40
XIX C10H10O2N2 60 63.15 5.30 14.73 0.38
190.20 126-128 63.20 5.19 14.64
XX C10H10O2N2 57 63.15 5.30 14.73 0.50
190.20 141-143 63.07 5.20 14.67
XXI C10H10O2N2 62 63.15 5.30 14.73 0.60
190.20 148-150 63.10 5.25 14.70
XXII C11H12O2N2 61 64.69 5.92 13.72 0.63
204.23 195-197 64.75 5.60 13.65
a) Developing system: chloroform : acetone (9 : 1, v/v).
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within the range of δ 0.95-0.96 ppm. All the aromat-
ic protons were well separated and observed at the
expected region. The detailed spectral data of each
compound are presented in Tables 2-4.
EXPERIMENTAL
Chemistry
All the chemicals and solvents were pur-
chased from Merck (Darmstadt, Germany) and
were used without further purification. Melting
points (m. p.) were determined in open capillaries
on a B¸chi 353 melting point apparatus (B¸chi
Labortechnik, Flawil, Switzerland) and are uncor-
rected. The purity of the compounds was con-
firmed by the thin-layer chromatography (TLC)
performed on Merck silica gel 60 F254 aluminium
sheets (Merck; Darmstadt, Germany), using the
developing system: chloroform : acetone (9 : 1,
v/v). Spots were detected by their absorption under
UV light (λ = 254 nm) and by visualization with
0.05 mol I2 in 10% HCl. The chemical structures
were confirmed by elemental and spectral analyses
(1H NMR). 1H NMR spectra were obtained on a
Varian Mercury 300 MHz spectrometer (Varian
Inc., Palo Alto, CA, USA), in CDCl3, with TMS as
an internal standard. Chemical shifts are reported
in δ values (ppm) and J values in hertz (Hz). Signal
multiplicities are represented by the following
abbreviations: s (singlet), d (doublet), t (triplet), q
(quartet), m (multiplet). Elemental analyses for C,
H, N were carried out with an Elementar Vario EL
III (Hanau, Germany) and were within ± 0.4% of
the theoretical values. The physicochemical data,
yields, elemental analyses and Rf values are pre-
sented in Table 1. The 1H NMR data are shown in
Tables 2-4.
General procedure for the preparation of com-
pounds I-XXII
0.01 mol of the appropriately substituted 2-
aminopyridine was dissolved in 20 mL of water and
0.01 mol of corresponding 2-substituted succinic
acid [I-XVIII] or succinic anhydride [XIX-XXII]
was gradually added. The mixture was heated in an
oil bath with simultaneous distillation of water.
After the water was completely removed, the tem-
perature of the reaction mixture rose up to 180∞C
and was maintained for 1.5 h. The crude products
were recrystallized from isopropanol.
Pharmacology
Compounds I-XXII were pharmacologically
pre-evaluated within the Antiepileptic Drug
Table 2. 1H-NMR data of compounds I-VIII.
No. 1H NMR (CDCl3) δ (ppm) 
0.95-1.08 (m, 4H, 3H, CH3, 1H, cyclohexane), 1.20-1.91 (m, 8H, cyclohexane), 2.19 (s, 3H,
I CH3-pyridine), 2.77 (s, 2H, imide), 7.26-7.33 (m, 1H, pyridine), 7.66-7.69 (m, 1H, pyridine), 8.47 (d, 
1H, pyridine J = 4.6 Hz)
0.95 (d, 3H, CH3, J = 6.1 Hz), 0.98-1.07 (m, 1H, cyclohexane), 1.30-1.88 (m, 8H, cyclohexane), 2.41 
II (s, 3H, CH3-pyridine), 2.74 (s, 2H, imide), 7.09-7.18 (m, 2H, pyridine), 8.50 (d, 1H, J = 5.1 Hz, 
pyridine)
0.96 (d, 3H, CH3, J = 6.1 Hz), 0.99-1.07 (m, 1H, cyklohexane), 1.30-1.87 (m, 8H, cyclohexane), 2.59 
III (s, 3H, CH3-pyridine), 2.74 (s, 2H, imide), 7.04 (d, 1H, pyridine, J = 7.6 Hz), 7.20 (d, 1H, pyridine 
J = 7.6 Hz), 7.72 (t, 1H, pyridine, J = 7.6 Hz)
0.95 (d, 3H, CH3, J = 6.1 Hz), 1.02-1.07 (m, 1H, cyclohexane), 1.29-1.86 (m, 8H, cyclohexane), 2.35
IV (s, 3H, CH3-pyridine), 2.54 (s, 3H, CH3-pyridine), 2.72 (s, 2H, imide), 6.85 (s, 1H, pyridine), 7.03 
(s, 1H, pyridine)
1.07-1.40 (m, 5H, cyclohexane), 1.62-1.78 (m, 5H, cyclohexane), 2.03-2.13 (m, 1H, cyclohexane), 
V 2.20 (s, 3H, CH3-pyridine), 2.67-2.77 (m, 1H, imide), 2.84-3.04 (m, 2H, imide), 7.28-7.33 (m, 1H, 
pyridine), 7.65-7.69 (m, 1H, pyridine), 8.47 (d, 1H, pyridine, J = 4.8 Hz)
1.07-1.39 (m, 5H, cyclohexane), 1.61-1.83 (m, 5H, cyclohexane), 2.02-2.10 (m, 1H, cyclohexane), 
VI 2.42 (s, 3H, CH3-pyridine), 2.65-2.72 (m, 1H, imide), 2.83-2.98 (m, 2H, imide), 7.07 (s, 1H, 
pyridine), 7.17 (d, 1H, pyridine, J = 5.1 Hz), 8.50 (d, 1H, pyridine, J = 4.8 Hz,)
1.08-1.39 (m, 5H, cyclohexane), 1.59-1.81 (m, 5H, cyclohexane), 2.01-2.10 (m, 1H, cyclohexane), 
VII 2.59 (s, 3H, CH3-pyridine), 2.65-2.85 (m, 1H, imide), 2.92-2.98 (m, 2H, imide), 7.02 (d, 1H, pyridine, 
J = 7.6 Hz), 7.21 (d, 1H, pyridine, J = 7.6 Hz), 7.73 (t, 1H, pyridine, J = 7.6 Hz)
1.06-1.39 (m, 5H, cyclohexane), 1.61-1.81 (m, 5H, cyclohexane), 2.00-2.09 (m, 1H, cyclohexane), 
VIII 2.36 (s, 3H, CH3,), 2.54 (s, 3H, CH3-pyridine), 2.63-2.85 (m, 1H, imide), 2.90-2.97 (m, 2H, imide), 
6.83 (s, 1H, pyridine), 7.03 (s, 1H, pyridine)  
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Table 3. 1H-NMR data of compounds IX-XV.
No. 1H NMR (CDCl3) δ (ppm) 
IX
1.46 (d, 6H, CH3, CH3, J = 1.2 Hz), 2.19 (s, 3H, CH3-pyridine), 2.77 (d, 2H, imide, J = 2.3 Hz), 
7.29-7.33 (dd, 1H, pyridine, J = 4.8 Hz), 7.65-7.69 (m, 1H, pyridine), 8.46-8.48 (m, 1H, pyridine)
X
1.44 (s, 6H, CH3, CH3), 2.41 (s, 3H, CH3-pyridine), 2.74 (s, 2H, imide), 7.09-7.17 (m, 2H, 
pyridine), 8.49 (d, 1H, pyridine, J = 4.8 Hz)
XI
1.44 (s, 6H, CH3, CH3), 2.59 (s, 3H, CH3-pyridine), 2.74 (s, 2H, imide), 7.04 (d, 1H, pyridine, 
J = 7.9 Hz), 7.20 (d, 1H, pyridine, J = 7.6 Hz), 7.72 (t, 1H, pyridine, J = 7.6 Hz)
1.00-1.06 (m, 3H, -CH2-CH3), 1.44 (d, 3H, CH3 J = 2.5 Hz), 1.66-1.95 (m, 2H, -CH2-CH3), 2.20 (s, 
XII 3H, CH3-pyridine), 2.60-2.68 (m, 1H, imide), 2.82-2.89 (m, 1H. imide), 7.28-7.33 (m, 1H, pyridine),
7.66-7.70 (m, 1H, pyridine), 8.48 (d, 1H, pyridine J = 4.6 Hz)
1.00 (t, 3H, -CH2-CH3, J = 7.4 Hz), 1.42 (s, 3H, CH3), 1.65-1.93 (m, 2H, -CH2-CH3), 2.42 (s, 3H, 
XIII CH3-pyridine), 2.62-2.67 (m, 1H, imide), 2.81-2.86 (m, 1H, imide), 7.08 (s, 1H, pyridine), 7.17 (d, 
1H, pyridine, J = 5.1 Hz), 8.50 (d, 1H, pyridine, J = 4.8 Hz)
1.00 (t, 3H, -CH2-CH3, J = 7.4 Hz), 1.42 (s, 3H, CH3), 1.65-1.92 (m, 2H, -CH2-CH3), 2.59 (s, 4H, 
XIV 3H, CH3-pyridine, 1H, imide), 2.83 (d, 1H, imide, J = 18.2 Hz), 7.03 (d, 1H, pyridine, J = 7.6 Hz), 
7.20 (d, 1H, pyridine, J = 7.6 Hz), 7.72 (t, 1H, pyridine,  J = 7.6 Hz)
0.99 (t, 3H, -CH2-CH3, J = 7.4 Hz), 1.41 (s, 3H, CH3), 1.65-1.91 (m, 2H, -CH2-CH3), 2.35 (s, 3H 
XV CH3-pyridine), 2.54 (s, 3H, CH3-pyridine), 2.61 (d, 1H, imide, J = 18.2 Hz), 2.78 (d, 1H, imide,
J = 18.1 Hz), 6.84 (s, 1H, pyridine), 7.03 (s, 1H, pyridine)  
Table 4. 1H-NMR data of compounds XVI-XXII.
No. 1H NMR (CDCl3) δ (ppm) 
XVI 1.02 (q, 6H, -CH2-CH3, -CH2-CH3, J = 7.3 Hz), 1.70-1.94 (m, 4H, -CH2-CH3, -CH2-CH3), 2.19 (s, 
3H, CH3-pyridine), 2.73 (s, 2H, imide), 7.27-7.30 (q, 1H, pyridine, J = 4.8 Hz), 7.64-7.68 (m, 1H, 
pyridine), 8.45-8.48 (m, 1H, pyridine)
XVII 0.99 (t, 6H, -CH2-CH3, -CH2-CH3, J = 7.4 Hz), 1.65-1.92 (m, 4H, -CH2-CH3, -CH2-CH3), 2.41 (s, 
3H, CH3-pyridine), 2.70 (s, 2H, imide), 7.05 (s, 1H, pyridine), 7.15-7.17 (m, 1H, pyridine), 8.50 (d, 
1H, pyridine, J = 5.1 Hz)
XVIII 0.96-1.02 (m, 6H, -CH2-CH3, -CH2-CH3), 1.67-1.92 (m, -CH2-CH3, -CH2-CH3), 2.58 (s, 3H, CH3-
pyridine), 2.70 (s, 2H, imide), 7.01 (d, 1H, pyridine, J = 7.9 Hz), 7.19 (d, 1H, pyridine, J = 7.6 Hz), 
7.70 (t, 1H, pyridine, J = 7.8 Hz)
XIX 2.21 (s, 3H, CH3-pyridine), 2.94 (s, 4H, imide), 7.32 (dd, 1H, pyridine, J = 4.7 Hz), 7.67-7.70 (m, 1H, 
pyridine), 8.47 (dd, 1H, pyridine, J = 4.8 Hz)
XX 2.41 (s, 3H, CH3-pyridine), 2.90 (s, 4H, imide), 7.16-7.19 (m, 2H, pyridine), 8.49 (d, 1H, pyridine J = 
4.8 Hz)
XXI 2.59 (s, 3H, CH3-pyridine), 2.90 (s, 4H, imide), 7.06(d, 1H, pyridine, J = 7.6 Hz), 7.22 (d, 1H, 
pyridine, J = 7.6 Hz), 7.74 (t, 1H, pyridine J = 7.6 Hz)
XXII 2.36 (s, 3H, CH3-pyridine), 2.53 (s, 3H, CH3), 2.88 (s, 4H, imide), 6.87 (s, 1H, pyridine), 7.04 (s, 1H,
pyridine)
Development (ADD) Program using procedures
described elsewhere (20, 21).
Phase I studies of the compounds investigated
involved three testes: maximal electroshock seizure
(MES), subcutaneous pentylenetrazole seizure
(scPTZ) and neurological toxicity (TOX). Male
albino mice (CF #1 strain, weighing 18-25 g) were
used as experimental animals. 
In the MES test, an electrical stimulus (50
mA) of 0.2 s in duration was delivered via corneal
electrodes primed with an electrolyte solution con-
taining an anesthetic agent. Mice were tested using
the following doses: 30, 100 and 300 mg/kg of
compounds investigated. The compounds were
injected intraperitoneally as a suspension in a 0.5%
methylcellulose/water mixture, in a volume of 0.01
mL/g body weight. Abolition of the hindlimb tonic
extensor component indicates the test compoundís
ability to inhibit MES-induced seizure spread.
The scPTZ test utilizes of pentylenetetrazole
(85 mg/kg). This produces clonic seizures lasting for
a period of at least 5 s in 97% (CD97) of animals
tested. At the anticipated time of testing the
pentylenetetrazole was administrated subcutaneous-
ly. The compounds tested were dissolved in 0.9%
saline and injected intraperitoneally in mice at a vol-
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ume of 0.01 mL/g body weight. The animals were
observed over a 30 min period. Absence of clonic
seizures in the observed time period indicated an
ability of compounds to abolish the effect of
pentylenetetrazole on seizure threshold.
A neurological toxicity test (TOX) induced by
a compound was detected in mice using standard-
ized rotarod test. Untreated control mice, when
placed on the 6 rpm rotation rod, can maintain their
equilibrium for a prolonged period of time.
Neurological impairment can be demonstrated by
the inability of mice to maintain equilibrium for 1
min in each of three successive trials.
According to the ADD program, the activity of
the compounds investigated was classed with the
following categories: active at doses of 100 mg/kg
or less (class 1), active at doses greater than 100
mg/kg (class 2), inactive at 300 mg/kg (class 3). The
results of preliminary screening for compounds I-
XXII are presented in Table 5. 
Compound IX underwent phase VIa in which
was administrated orally into rats using four animals
at a fixed dose of 30 mg/kg for both the MES and the
rotarod toxicity tests. Rats were tested at five time
periods: 0.25, 0.5, 1, 2 and 4 h after substance
administration. The ratios of animals protected or
toxic to animals tested were determined. The initial
identification study in rats provides information as
Table 5. Anticonvulsant screening project (ASP) phase I in mice (I-XXII).
Compound Intraperitoneal injection in micea ASP
No. MES scPTZ TOXb Classc
0.5[h] 4[h] 0.5[h] 4[h] 0.5[h] 4[h]
I 300 - - - 3001 - 2
II 300 - 1002 - 1001 - 1
III - - 3002 - 100 - 2
IV 300 - - - 1001 - 2
V 300 - - - - - 2
VI - - 30 - 30 30 4
VII - - - - 3001 - 3
VIII - - - - 100 - 3
IX 300 - 300 - - - 2
Xd 300 - 300 - 3001 - 2
XI 300 - 100 - 3001 - 1
XII 300 - - - 3001 - 2
XIIId - - 300 - 300 - 2
XIV 300 - 100 - 100 - 1
XV 300 - 300 - 1001 - 2
XVI 300 - 300 - - - 2
XVII 100 - 300 - 1001 - 1
XVIIIe 300 - 300 - 3001 - 2
XIX - - - - 100 - 3
XX - - - - - - 3
XXI - - - - - - 3
XXII - - - - - - 3  
a Doses of 30, 100 and 300 mg/kg were administrated. The figures in the Table indicate the minimal dose (mg/kg), whereby bioactivity
was demonstrated. The dash (ñ) indicates an absence of activity at maximum dose administrated. 
b Toxicity screen: the minimum dose of compound whereby toxicity was exhibited. Response comments: 1 unable to grasp rotarod, 2
myoclonic jerks.
c The ASP classification is as follows: 1 ñ anticonvulsant activity at doses of 100 mg/kg or less; 2 ñ anticonvulsant activity at doses of
300 mg/kg; 3 ñ compound inactive at doses of 300 mg/kg; 4 ñ compound active, however, toxic at a dose of 30 mg/kg.
d Compounds X and XIII active at a dose of 100 mg/kg in scPTZ test at 0.25 h (X and XIII) or 1.0 h (X).
e Compound XVIII showed anti-MES protection at a dose of 100 mg/kg at 0.25 h.
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to whether the test substance is active or toxic at a
dose of 30 mg/kg after p.o. administration. It dis-
closes also the time of onset, the approximate time
of peak effect (TPE) and the duration of anticonvul-
sant activity or neurotoxicity (Table 6).
Compound XIII was tested in the 6-Hz psy-
chomotor seizure screen. For this test twenty mice
are pre-treated i.p. with 100 mg/kg of the test sub-
stance. At time points: 0.25, 0.5, 1, 2 and 4 h after
treatment, individual mice (4 in each time point)
are challenged with sufficient current (32 mA at 6
Hz for 3 s), delivered through the corneal elec-
trodes to induce a psychomotor seizures. This
seizure is typically characterized by a minimal
clonic phase followed by stereotyped behaviors.
Animals which not display this symptoms are con-
sidered protected (22).
RESULTS
The profile of anticonvulsant activity of com-
pounds I-XXII was established and the results of
anticonvulsant identification studies in mice are
shown in Table 5.
The compounds investigated I-XXII showed
diversified anticonvulsant properties from active at a
dose of 100 mg/kg or less (class 1 ASP) [II, XI,
XIV and XVII], to active at a dose of 300 mg/kg
(class 2 ASP) [I, III-V, IX, X, XII, XIII, XV, XVI
and XVIII] and inactive ones (class 3 ASP) [VII,
VIII and XIX-XXII].
The most potent anti-seizure protection was
observed for 3,3-dialkyl-pyrrolidine-2,5-diones [IX-
XVIII]. In this group of derivatives, except of XII
and XIII active in the MES or scPTZ screen, respec-
tively, all other compounds were effective in both
tests applied. In general, the most active were mole-
cules with the methyl substituent at position-4 [X
and XVII] or -6 [XI, XIV and XVIII] of the 2-
pyridinyl moiety. These substances showed anti-
MES protection at a dose of 100 mg/kg at 0.25 h
[XVIII] or 0.5 h [XVII] and 300 mg/kg at 0.5 h [X,
XI, XIV and XVIII]. The anti-scPTZ activity was
observed at a dose of 100 mg/kg at 0.25 h [X and
XIII], 0.5 h [XI and XIV] or 1.0 h [X] and 300
mg/kg at 0.5 h [X, XIII, XVII and XVIII]. The 3-
methyl isomers [IX and XVI] as well as compound
XV with two methyl groups at position-4,6 of the 2-
pyridinyl ring inhibited MES and scPTZ seizures at
a dose of 300 mg/kg at 0.5 h. The further investiga-
tions revealed that an introduction of spiro nucleus
yielded less active compounds I-IV. Among these
derivatives, the most effective was 1-(4-methyl-2-
pyridinyl)-7-methyl-2-azaspiro[4.5]decane-1,3-
dione [II] which showed the anti-scPTZ and anti-
MES protection at a dose of 100 mg/kg and 300
mg/kg, respectively. The other molecules were
active only in MES [I and IV] or scPTZ [III] screen
at 0.5 h after intraperitoneal administration.
To evaluate the effect of the cycloalkyl frag-
ment attached to the C3 spiro carbon atom on anti-
convulsant activity of spirosuccinimides [I-IV] as
well as compounds described previously (16), the
series of 3-cyclohexyl-pyrrolidine-2,5-dione deriva-
tives [V-VIII] has been synthesized. These mole-
cules were designed as the analogs of the respective
active spirosuccinimides. The results obtained
revealed that the introduction of the cyclohexyl moi-
ety as a flexible fragment at position-3 of the imide
ring made the compounds less active [V] or inactive
[VII and VIII]. Surprisingly, 1-(4-methyl-2-
pyridinyl)-3-cyclohexyl-pyrrolidne-2,5-dione [VI]
showed protection at a dose of 30 mg/k at 0.5 h in
the scPTZ test and was the most active derivative
among all compound described herein. This mole-
cule revealed, however, neurotoxicity at a dose of 30
mg/kg and regardless of its activity according to the
procedures of ADD Program was ascribed to 4 ASP
class. As shown in Table 1, compounds XIX-XXII
without substituents at the 3-position of pyrrolidine-
2,5-dione ring were inactive.
In the neurotoxicity screen only compounds V,
IX, XVI and XX-XXI were devoid of toxicity at a
maximal dose administrated (300 mg/kg). The other
derivatives were found to be toxic at a dose of 100
mg/kg [II-IV, VIII, XIV, XV, XVII and XIX] or
Table 6. The results in rats after oral administration at a dose of 30 mg/kg.
Compound Oral administration to rats 
No. MESa TOXb
0.25[h] 0.5[h] 1[h] 2[h] 4[h] 0.25[h] 0.5[h] 1[h] 2[h] 4[h]
IX 1/4 1/4 1/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4
a Maximal electroshock test, number of animals protected/number of animals tested.
b Rotarod test for neurological toxicity, number of animals exhibiting toxicity/number of animals tested.
464 KRZYSZTOF KAMI—SKI and JOLANTA OBNISKA
300 mg/kg [I, VII, X-XIII, XV and XVIII]. Mice
were unable to grasp rotarod after administration of
compounds I, II, IV, VII, X-XII, XV, XVII and
XVIII.
Compound IX, randomly selected from deriva-
tives active in i.p. screen in mice, was examined for
its activity (MES test) and toxicity at a dose of 30
mg/kg after p.o. administration into rats. The tested
substance showed marginal protection of 25% of
animals at 0.25 h, 0.5 h and 1 h. The total duration
of action of this compound was quite short within
0.25 h to 1 h. No evidence of neurological toxicity
was observed at the dose of 30 mg/kg administrated
orally (Table 6).
Compound XIII was chosen for the evaluation
of anticonvulsant activity in the 6 Hz test. The selec-
tion was made randomly as a part of the search of
molecules providing anti-6-Hz protection among
chemically diversified compounds. The 6-Hz screen
described previously as psychomotor seizure model
reminiscent of aura of human patients with partial or
limbic epilepsy (23-26), more recently has been val-
idated as a model of therapy-resistant epilepsy (27).
Furthermore, substances effective in the above test
may reveal novel, unknown mechanism of anticon-
vulsant activity. Compound XIII administrated
intraperitoneally at a dose of 60 mg/kg into mice
protected 100% of animals tested only at 0.25 h,
however, at the same time point caused the motor
impairment.
In conclusion, the results obtained revealed
that a number of new 1-(2-pyridinyl)- derivatives of
succinimides were effective in MES and/or scPTZ
screens. The most active were compounds with two
alkyl substituents at position-3 of pyrrolidine-2,5-
dione, which may be recognized as close analogues
of ethosuximide (2-ethyl-2-methyl-pyrrolidine-2,5-
dione), known as one of the not numerous anticon-
vulsants effective in the treatment of absence epilep-
sy (28, 29). Furthermore, comparison of results
obtained for the spirosuccinimides and compounds
with cyclohexyl moiety as a flexible fragment at
position-3 of the imide ring, proved an essential role
of cycloalkyl system attached through the C3 spiro
carbon atom for anticonvulsant activity of that type
of compounds. The presence of methyl groups espe-
cially in position-4 or -6 of 2-pyridinyl moiety
seems to be favorable for anti-seizures properties.
This was contrary to our earlier experiments (10-16)
indicating the important role of the 3-methyl substi-
tution. The lack of any substituents at position-3 of
succinimide moiety causes the loss of anticonvul-
sant activity as well as toxicity.
In summary, none of the compounds described here-
in was more potent that the molecules with an aryl
moiety at position-3 of pyrrolidine-2,5-dione ring
(10-12), however, the interesting pharmacological
results encourage to continue further investigations
in this group of derivatives.
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